# Do GLP-1 Drugs Help Rheumatoid Arthritis? The Heart Result, Not the Joints Do GLP-1 drugs help rheumatoid arthritis? 1,017 matched pairs, a MACCE hazard ratio of 0.75 driven entirely by heart failure, and no measurement of joint disease. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-help-rheumatoid-arthritis Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Help Rheumatoid Arthritis? The Heart Result, Not the Joints Semaglutide was linked to fewer cardiovascular events in people with rheumatoid arthritis. Heart failure accounted for it; death, heart attack and stroke did not budge. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min read Semaglutide vs other second-line drugs · MACCE (composite) · 0.75 · heart failure · 0.69 · death, MI, stroke · no significant difference · 1,017 matched pairs, followed up to two years. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Not the joints, on this evidence. Among 1,017 matched pairs with type 2 diabetes, rheumatoid arthritis and obesity, semaglutide was associated with major adverse cardiac and cerebrovascular events in 12.7% against 16.5%, a hazard ratio of 0.75 (95% CI 0.60 to 0.94) [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-rheumatoid-arthritis#ref-1). The composite moved because heart failure moved, at 8.9% against 12.5%, while death, heart attack and stroke showed no significant difference at all. Nothing in the study measured joint disease. The inflammation these drugs are shown to lower is a blood marker: high-sensitivity CRP fell 37.8% at 104 weeks in SELECT [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-rheumatoid-arthritis#ref-2). ## Key takeaways - Among 1,017 matched pairs with type 2 diabetes, rheumatoid arthritis and obesity, semaglutide was associated with fewer major cardiovascular and cerebrovascular events: 12.7% vs 16.5% (HR 0.75, 95% CI 0.60-0.94). - The composite moved because heart failure moved: 8.9% vs 12.5% (HR 0.69, 95% CI 0.53-0.91). - All-cause mortality, myocardial infarction and stroke showed no significant differences. - Escalation to a disease-modifying antirheumatic drug was also lower (16.6% vs 21.6%), which is a prescribing observation rather than a measure of disease activity. Rheumatoid arthritis makes exercise painful and weight management harder, and it adds chronic inflammation on top, so cardiovascular risk in this group is elevated for several reasons at once. A target trial emulation in a US database asked whether semaglutide changes that, comparing 1,017 matched pairs who started it against other second-line glucose-lowering drugs[\[1\]](https://thisglp.com/research/do-glp1-drugs-help-rheumatoid-arthritis#ref-1). Everyone was free of prior stroke, heart failure and coronary events, making this a primary-prevention question, which is a harder one than the [established heart failure evidence](https://thisglp.com/research/do-glp1-drugs-help-heart-failure) addresses. The composite outcome separated. Major adverse cardiovascular and cerebrovascular events occurred in 12.7% against 16.5%, a hazard ratio of 0.75 (95% CI 0.60–0.94, P = .01). One of four components did the work The composite bundles death, heart attack, heart failure and stroke. Heart failure came in at 8.9% against 12.5% (HR 0.69, 95% CI 0.53–0.91). Mortality, myocardial infarction and stroke showed no significant differences at all. Describing this as a reduction in cardiovascular events is technically accurate and practically misleading — it is a heart failure result wearing a composite's clothes. Heart failure is also the component where a weight drug has the clearest non-vascular route to an effect. It is diagnosed substantially on symptoms, breathlessness on exertion chief among them, and removing a tenth of someone's body weight changes how far they can walk before they are short of breath. A real reduction in cardiac strain and a change in what gets coded both produce this number, and two years of follow-up in a thousand pairs cannot separate them. The same detection problem, with the two endpoints disagreeing rather than agreeing, appears in [the carpal tunnel cohort](https://thisglp.com/research/do-glp1-drugs-help-carpal-tunnel-syndrome). ## What happens when a joint is measured directly Rheumatoid arthritis has not been measured that way, and the nearest thing is osteoarthritis. Ninety-three adults with knee osteoarthritis started semaglutide in routine rheumatology care and 88 completed six months, over which mean weight fell 10.88 kg, pain fell 2.47 points and the WOMAC total fell 22.50 points [\[3\]](https://thisglp.com/research/do-glp1-drugs-help-rheumatoid-arthritis#ref-3). C-reactive protein fell 2.67 mg/L and the sedimentation rate 7.62 mm/h. There was no untreated comparison group, and the authors state in their own methods that the changes are therefore non-causal, which is rarer than the result and worth more. Osteoarthritis is mechanical and rheumatoid arthritis is autoimmune, so this is an adjacent measurement rather than a stand-in, and the randomized version of it sits in [the knee pain trial](https://thisglp.com/research/do-glp1-drugs-help-knee-pain). Escalation to a disease-modifying antirheumatic drug was lower as well, 16.6% against 21.6% (HR 0.75, 95% CI 0.60–0.90). The temptation is to read that as less active arthritis, and it should be resisted for the reason set out in [the Crohn's disease cohort](https://thisglp.com/research/do-glp1-drugs-help-crohns-disease). There, a lower rate of recorded biologic use could not be distinguished from a change in prescribing patterns. A claims database sees the prescription, not the joint. The authors ask for prospective work and apply a Bonferroni correction for their secondary comparisons, both of which are the right instincts. What survives is a plausible, modest, single-component finding in a group that gets studied rarely. It is also a reminder that the weight itself does things a composite endpoint will happily absorb, including to muscle, as covered in [what these drugs do to muscle](https://thisglp.com/research/muscle-loss-on-glp1). ## Frequently asked Do GLP-1 drugs help rheumatoid arthritis? No study has measured joint disease activity. The one target trial emulation in this population measured cardiovascular events and found 12.7% against 16.5%, a hazard ratio of 0.75 carried entirely by the heart failure component. Did semaglutide prevent heart attacks and strokes here? No. Myocardial infarction, stroke and all-cause mortality showed no significant differences. The composite result was driven by the heart failure component alone. Why single out heart failure? It is the component most sensitive to weight, and it is diagnosed largely on symptoms like breathlessness. Losing a tenth of body weight changes those symptoms, so a coding shift and a real cardiac effect look alike in this data. Does it reduce arthritis activity? That is not established. Escalation to a disease-modifying drug was lower, but a claims database records prescriptions rather than joint disease, and cannot separate starting a drug from continuing one. ## Sources 1. \[1\] Malik F, Shah M, Chang Y, Chowdhury I, et al. (2026). Semaglutide for primary prevention of major adverse cardiac and cerebrovascular events in patients with type 2 diabetes and comorbid rheumatoid arthritis: a target-trial emulation European Heart Journal. Cardiovascular Pharmacotherapy. [PMID 42334436](https://pubmed.ncbi.nlm.nih.gov/42334436/) 2. \[2\] Plutzky J, Bogdański P, Colhoun HM, Dağdelen S, et al. (2026). Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis Circulation. [PMID 42610271](https://pubmed.ncbi.nlm.nih.gov/42610271/) 3. \[3\] Conforti A, et al. (2026). Beyond the Scale: Changes in Pain, Physical Function (WOMAC), and Low-Grade Inflammation Following Semaglutide Treatment in Patients with Knee Osteoarthritis-Results from a Six-Month Real-World Cohort Journal of Clinical Medicine. [PMID 42589980](https://pubmed.ncbi.nlm.nih.gov/42589980/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)